| Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met T Damghani, F Moosavi, M Khoshneviszadeh, M Mortazavi, S Pirhadi, ... Scientific Reports 11 (1), 3644, 2021 | 25 | 2021 |
| Critical c-Met-inhibitor interactions resolved from molecular dynamics simulations of different c-Met complexes T Damghani, T Sedghamiz, S Sharifi, S Pirhadi Journal of Molecular Structure 1203, 127456, 2020 | 23 | 2020 |
| Copper-catalyzed S-arylation of tetramethylguanidine–heterocumulene adducts I Yavari, M Nematpour, T Damghani Tetrahedron Letters 55 (7), 1323-1325, 2014 | 18 | 2014 |
| Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3, 4-dihydropyrimidin-2 (1H)-one C5 amide derivatives F Moosavi, A Ebadi, M Mohabbati, T Damghani, M Mortazavi, R Miri, ... European Journal of Pharmacology, 173850, 2021 | 16 | 2021 |
| N-sulfonyl ketenimine as a versatile intermediate for the synthesis of heteroatom containing compounds S Bahadorikhalili, M Divar, T Damghani, F Moeini, S Ghassamipour, ... Journal of Organometallic Chemistry 939, 121773, 2021 | 15 | 2021 |
| Sulfonoketenimides as key intermediates for the synthesis of 2-thioxo-2-1,3-thiazines and 2-arylimino-2-1,3-thiazines I Yavari, M Nematpour, T Damghani Molecular diversity 17 (4), 801-808, 2013 | 13 | 2013 |
| Design, synthesis, in vitro evaluation and molecular docking study of N'-Arylidene imidazo [1, 2-a] pyridine-2-carbohydrazide derivatives as novel tyrosinase inhibitors T Damghani, S Hadaegh, S Pirhadi, R Sabet, M Khoshneviszadeh, ... Journal of Molecular Structure 1222, 128876, 2020 | 12 | 2020 |
| Copper-Catalyzed One-Pot Synthesis of N-Sulfonylalkanimidoyl Thiocyanates from Sulfonyl Azides, Alkynes, and KSCN. I Yavari, T Damghani, M Nematpour Helvetica Chimica Acta 96 (12), 2013 | 12 | 2013 |
| Dual potent c-Met and ALK inhibitors: from common feature pharmacophore modeling to structure based virtual screening S Pirhadi, T Damghani, MS Avestan, S Sharifi Journal of Receptors and Signal Transduction 40 (4), 357-364, 2020 | 9 | 2020 |
| Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition Tahereh Damghani, Maryam Elyasi, Somayeh Pirhadi, Haghighijoo Zahra, Somayeh ... Molecular Diversity, 2021 | 7* | 2021 |
| Benzyl‐Triazole Derivatives of Hydrazinecarbothiamide Derivatives as Potent Tyrosinase Inhibitors: Synthesis, Biological Evaluation, Structure‐Activity Relationship and Docking … M Divar, S Tadayyon, M Khoshneviszadeh, S Pirhadi, M Attarroshan, ... ChemistrySelect 8 (8), e202203382, 2023 | 4 | 2023 |
| In silico screening of c-Met tyrosine kinase inhibitors targeting nucleotide and drug-substrate binding sites of ABCB1 as potential MDR reversal agents F Moosavi, T Damghani, S Ghazi, S Pirhadi Journal of Receptors and Signal Transduction 42 (6), 549-561, 2022 | 4 | 2022 |
| Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors O Mortazavi, Motahareh Divar, Masoumeh Damghani, Tahereh Moosavi, Fatemeh ... Frontiers in Chemistry, 1381, 2022 | 4* | 2022 |
| Clustering and Sampling of the c-Met Conformational Space: A Computational Drug Discovery Study K Mashayekh, S Sharifi, T Damghani, M Elyasi, MS Avestan, S Pirhadi Combinatorial chemistry & high throughput screening 22 (9), 635-648, 2019 | 4 | 2019 |
| Prediction of cytotoxic activity of a series of 1H-pyrrolo [2, 3-b] pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints T Damghani, K Mashayekh, S Pirhadi, O Firuzi, S Sharifi, N Edraki, ... Journal of Receptors and Signal Transduction 39 (4), 295-303, 2019 | 4 | 2019 |
| Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors. T Damghani, F Wittlinger, TS Beyett, MJ Eck, SA Laufer, DE Heppner | 3 | 2023 |
| Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design. F Wittlinger, BC Ogboo, CD Pham, IK Schaeffner, SP Chitnis, T Damghani, ... | 3 | 2023 |
| Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitors M Divar, N Edraki, T Damghani, F Moosavi, M Mohabbati, A Alipour, ... Bioorganic & Medicinal Chemistry 90, 117367, 2023 | 2 | 2023 |
| Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library OF Motahareh Mortazavi, Elaheh Raufi, Tahereh Damghani, Mehdy ... European Journal of Pharmacology, 2022 | 2* | 2022 |
| Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors F Wittlinger, BC Ogboo, E Shevchenko, T Damghani, CD Pham, ... Communications Chemistry 7 (1), 38, 2024 | 1 | 2024 |
Somayeh PirhadiUniversity of PittsburghVerified email at pitt.edu
